Q BioMed Inc. (QBIO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 4.06 Million USD | 49.87% |
| 2021 | 2.7 Million USD | 3288.59% |
| 2020 | -84.96 Thousand USD | -102.42% |
| 2019 | 3.51 Million USD | 1762.76% |
| 2018 | 188.85 Thousand USD | 122.9% |
| 2017 | -824.78 Thousand USD | -165.57% |
| 2016 | 1.25 Million USD | 664.19% |
| 2015 | 164.59 Thousand USD | 1401.23% |
| 2014 | -12.64 Thousand USD | 49.4% |
| 2013 | -25 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 4.06 Million USD | 0.0% |
| 2023 Q2 | - USD | -100.0% |
| 2022 Q2 | 3.38 Million USD | 5.58% |
| 2022 Q4 | 4.06 Million USD | 11.69% |
| 2022 Q3 | 3.63 Million USD | 7.28% |
| 2022 FY | 4.06 Million USD | 49.87% |
| 2022 Q1 | 3.2 Million USD | 18.46% |
| 2021 Q2 | 709.13 Thousand USD | 56.18% |
| 2021 FY | 2.7 Million USD | 3288.59% |
| 2021 Q4 | 2.7 Million USD | 160.71% |
| 2021 Q3 | 1.03 Million USD | 46.53% |
| 2021 Q1 | 454.05 Thousand USD | 634.43% |
| 2020 Q1 | 3.86 Million USD | 9.92% |
| 2020 Q4 | -84.96 Thousand USD | 93.13% |
| 2020 FY | -84.96 Thousand USD | -102.42% |
| 2020 Q2 | -2.92 Million USD | -175.59% |
| 2020 Q3 | -1.23 Million USD | 57.71% |
| 2019 Q4 | 3.51 Million USD | -15.43% |
| 2019 Q3 | 4.16 Million USD | 19.17% |
| 2019 Q2 | 3.49 Million USD | 91.5% |
| 2019 FY | 3.51 Million USD | 1762.76% |
| 2019 Q1 | 1.82 Million USD | 865.23% |
| 2018 Q1 | -4.18 Million USD | -407.65% |
| 2018 FY | 188.85 Thousand USD | 122.9% |
| 2018 Q4 | 188.85 Thousand USD | 124.0% |
| 2018 Q3 | -786.85 Thousand USD | 66.14% |
| 2018 Q2 | -2.32 Million USD | 44.49% |
| 2017 FY | -824.78 Thousand USD | -165.57% |
| 2017 Q4 | -824.78 Thousand USD | -88.38% |
| 2017 Q3 | -437.83 Thousand USD | -127.4% |
| 2017 Q2 | 1.59 Million USD | 21.38% |
| 2017 Q1 | 1.31 Million USD | 4.65% |
| 2016 FY | 1.25 Million USD | 664.19% |
| 2016 Q1 | 700.12 Thousand USD | 325.37% |
| 2016 Q3 | 1.12 Million USD | 26.95% |
| 2016 Q2 | 887.2 Thousand USD | 26.72% |
| 2016 Q4 | 1.25 Million USD | 11.67% |
| 2015 FY | 164.59 Thousand USD | 1401.23% |
| 2015 Q1 | -3365.00 USD | 73.4% |
| 2015 Q4 | 164.59 Thousand USD | 164692.0% |
| 2015 Q2 | -715.00 USD | 78.75% |
| 2015 Q3 | -100.00 USD | 86.01% |
| 2014 Q4 | -12.64 Thousand USD | 59.77% |
| 2014 Q1 | -17.22 Thousand USD | 0.0% |
| 2014 Q3 | -31.44 Thousand USD | -150.3% |
| 2014 Q2 | -12.56 Thousand USD | 27.05% |
| 2014 FY | -12.64 Thousand USD | 49.4% |
| 2013 FY | -25 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 310024.275% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 28.121% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 90.512% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1726.475% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1231.15% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 164.398% |
| Qrons Inc. | 351.42 Thousand USD | -1055.292% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -552.353% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 90.652% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 19994.198% |
| Skye Bioscience, Inc. | -5.72 Million USD | 170.962% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 74.243% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 1.409% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -910.332% |
| SQZ Biotechnologies Company | -36.23 Million USD | 111.204% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -81.07% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -337.885% |
| Mesoblast Limited | 55.85 Million USD | 92.732% |
| Marizyme, Inc. | 18.56 Million USD | 78.136% |
| Genus plc | 190.6 Million USD | 97.87% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -81.588% |
| Pharming Group N.V. | 109.8 Million USD | 96.302% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -371.962% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -234.463% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -497.06% |
| ContraFect Corporation | -6.02 Million USD | 167.375% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -2915.477% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -251.385% |
| IMV Inc. | 7.67 Million USD | 47.07% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 26.207% |
| MultiCell Technologies, Inc. | 90.04 USD | -4509015.948% |
| ONE Bio Corp. | 9.04 Million USD | 55.089% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 653.151% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 68.639% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -196.791% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 86.712% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -302.892% |
| Biomind Labs Inc. | 711.4 Thousand USD | -470.705% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 93.294% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -103.062% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 68.298% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1028.689% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -2804.071% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -20335.939% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -84.38% |
| GB Sciences, Inc. | 1.74 Million USD | -132.357% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 2309.071% |
| HST Global, Inc. | 96.79 Thousand USD | -4094.526% |
| CSL Limited | 10.52 Billion USD | 99.961% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -1868.804% |
| Halberd Corporation | 144.72 Thousand USD | -2705.404% |
| Enzolytics Inc. | 981.65 Thousand USD | -313.588% |
| Agentix Corp. | 37.63 Thousand USD | -10688.998% |
| Resverlogix Corp. | 6.45 Million USD | 37.064% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 703.19% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.2% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 108.636% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 42.582% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -49.892% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 145.928% |
| AVAX Technologies, Inc. | -5.9 Million USD | 168.776% |
| Zenith Capital Corp. | 10.06 Thousand USD | -40241.892% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.383% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1925.629% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -70.157% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -2367.955% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 22264.035% |
| Kadimastem Ltd | -253.1 Thousand USD | 1704.1% |
| Helix BioMedix, Inc. | -2.57 Million USD | 257.975% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 79.976% |
| BioStem Technologies, Inc. | 4.47 Million USD | 9.213% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1917.355% |
| LadRx Corporation | -2.03 Million USD | 299.365% |
| Cell Source, Inc. | 9.23 Million USD | 56.022% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -539.203% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -539.203% |
| NovAccess Global Inc. | 2.17 Million USD | -86.37% |
| Affymax, Inc. | -5.59 Million USD | 172.539% |
| Itoco Inc. | 228.3 Thousand USD | -1678.326% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -2885.541% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 18.095% |
| Mobile Lads Corp. | 484.23 Thousand USD | -738.443% |
| CytoDyn Inc. | 20.26 Million USD | 79.962% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 627612.828% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 43905.126% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 47.314% |
| SYBLEU INC | 473.71 Thousand USD | -757.059% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 8.908% |
| International Stem Cell Corporation | 2.59 Million USD | -56.757% |
| Bioxytran, Inc. | 1.89 Million USD | -113.807% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -6405.068% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -86.162% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -18.23% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 52.531% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -425.495% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 424.801% |
| Neutra Corp. | 52.18 Thousand USD | -7679.731% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 263.118% |
| PureTech Health plc | -167.19 Million USD | 102.428% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1757.769% |
| IXICO plc | -4.44 Million USD | 191.347% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 69.287% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 92.598% |
| CSL Limited | 10.52 Billion USD | 99.961% |
| Cellectis S.A. | -43.81 Million USD | 109.265% |